Trials / Completed
CompletedNCT02888236
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study of LEO 32731 in the treatment of psoriasis vulgaris
Detailed description
This is an investigation of the efficacy of LEO 32731 30 mg as compared to placebo after 16 weeks of oral treatment of psoriasis vulgaris
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 32731 | |
| DRUG | LEO 32731 Placebo |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-06-20
- Completion
- 2017-07-06
- First posted
- 2016-09-02
- Last updated
- 2017-08-28
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02888236. Inclusion in this directory is not an endorsement.